Rankings
▼
Calendar
AXSM Q2 2025 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AXSM
Axsome Therapeutics, Inc.
$9B
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$150M
+72.1% YoY
Gross Profit
$137M
91.0% margin
Operating Income
-$37M
-24.5% margin
Net Income
-$48M
-32.0% margin
EPS (Diluted)
$-0.97
QoQ Revenue Growth
+23.5%
Cash Flow
Operating Cash Flow
-$32M
Free Cash Flow
-$32M
Stock-Based Comp.
$25M
Balance Sheet
Total Assets
$640M
Total Liabilities
$567M
Stockholders' Equity
$73M
Cash & Equivalents
$303M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$150M
$87M
+72.1%
Gross Profit
$137M
$79M
+72.7%
Operating Income
-$37M
-$78M
+53.0%
Net Income
-$48M
-$79M
+39.5%
Revenue Segments
Product
$149M
99%
Royalty
$1M
1%
Geographic Segments
UNITED STATES
$146M
98%
Non-US
$3M
2%
← FY 2025
All Quarters
Q3 2025 →